Product Description
Mechanisms of Action: CD23 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia
Phase 1: Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, B-Cell
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00058396 |
IDEC-152-20 | P1 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, B-Cell |
2004-10-01 |
2019-03-21 |
Treatments |
|
2006-002987-24 |
Lumiliximab in combination with FCR in the treatment of relapsed CLL | P2 |
Completed |
Chronic Lymphoid Leukemia |
2010-12-25 |
2022-03-12 |
Treatments |
|
NCT00391066 |
LUCID | P2 |
Terminated |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2010-07-01 |
2019-03-21 |
Treatments |
|
NCT00801060 |
152CL202 | P2 |
Terminated |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2010-06-01 |
2019-03-18 |
||
2008-002204-25 |
2008-002204-25 | P2 |
Terminated |
Chronic Lymphoid Leukemia |
2010-03-22 |
2022-03-12 |
Treatments |
|
NCT00103558 |
NCT00103558 | P2 |
Completed |
Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2010-01-01 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|